A 2025 phase I/II trial of iadademstat (LSD1 inhibitor) + venetoclax + azacitidine reported a 60% CR/CRh rate in venetoclax-naive AML (Cortes et al., 2025). Here, KDM1A is linked to acute myeloid leukemia.